SG11201800326YA - Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor - Google Patents
Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitorInfo
- Publication number
- SG11201800326YA SG11201800326YA SG11201800326YA SG11201800326YA SG11201800326YA SG 11201800326Y A SG11201800326Y A SG 11201800326YA SG 11201800326Y A SG11201800326Y A SG 11201800326YA SG 11201800326Y A SG11201800326Y A SG 11201800326YA SG 11201800326Y A SG11201800326Y A SG 11201800326YA
- Authority
- SG
- Singapore
- Prior art keywords
- aggrus
- clec
- binding
- screening
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015140998 | 2015-07-15 | ||
JP2015211883 | 2015-10-28 | ||
PCT/JP2016/070466 WO2017010463A1 (ja) | 2015-07-15 | 2016-07-11 | 抗Aggrusモノクローナル抗体、CLEC-2との結合に必要なAggrusの領域、及びAggrus-CLEC‐2結合阻害剤のスクリーニング方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201800326YA true SG11201800326YA (en) | 2018-02-27 |
Family
ID=57757420
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913225SA SG10201913225SA (en) | 2015-07-15 | 2016-07-11 | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor |
SG11201800326YA SG11201800326YA (en) | 2015-07-15 | 2016-07-11 | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913225SA SG10201913225SA (en) | 2015-07-15 | 2016-07-11 | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor |
Country Status (8)
Country | Link |
---|---|
US (2) | US10730939B2 (ja) |
EP (1) | EP3323831B1 (ja) |
JP (2) | JP6803840B2 (ja) |
KR (1) | KR20180023951A (ja) |
CN (2) | CN107849138B (ja) |
ES (1) | ES2949317T3 (ja) |
SG (2) | SG10201913225SA (ja) |
WO (1) | WO2017010463A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3323831B1 (en) * | 2015-07-15 | 2023-04-12 | Japanese Foundation For Cancer Research | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor |
CN106947744B (zh) * | 2017-03-14 | 2020-05-05 | 福州迈新生物技术开发有限公司 | 一株分泌抗平足蛋白单克隆抗体的杂交瘤细胞株及其应用 |
US11306152B2 (en) | 2017-03-30 | 2022-04-19 | Tohoku University | Anti-podoplanin antibody |
US20210132072A1 (en) | 2017-10-26 | 2021-05-06 | Vib Vzw | Podoplanin positive macrophages |
KR20210141794A (ko) | 2019-03-15 | 2021-11-23 | 고에키자이단호진 간겐큐카이 | 항포도플라닌 항체 |
EP3939997A4 (en) * | 2019-03-15 | 2022-12-07 | Japanese Foundation For Cancer Research | ANTI-PODOPLANIN ANTIBODIES |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4721633B2 (ja) | 2002-10-11 | 2011-07-13 | 財団法人癌研究会 | 血小板凝集促進活性を有する物質 |
CN1778822A (zh) * | 2004-11-24 | 2006-05-31 | 中国人民解放军第二军医大学 | C型凝集素样受体l1的单克隆抗体及其制备和应用 |
KR101956566B1 (ko) | 2011-03-22 | 2019-03-11 | 고에키자이단호진 간겐큐카이 | 마우스 항Aggrus 모노클로날 항체 |
JP2013071916A (ja) | 2011-09-28 | 2013-04-22 | General Incorporated Association Pharma Valley Project Supporting Organization | 3−アリールオキシクロモン化合物を有効成分とする血小板凝集抑制剤 |
WO2015053381A1 (ja) * | 2013-10-10 | 2015-04-16 | 幸成 加藤 | 抗ポドプラニン抗体 |
EP3323831B1 (en) * | 2015-07-15 | 2023-04-12 | Japanese Foundation For Cancer Research | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor |
-
2016
- 2016-07-11 EP EP16824443.2A patent/EP3323831B1/en active Active
- 2016-07-11 ES ES16824443T patent/ES2949317T3/es active Active
- 2016-07-11 SG SG10201913225SA patent/SG10201913225SA/en unknown
- 2016-07-11 SG SG11201800326YA patent/SG11201800326YA/en unknown
- 2016-07-11 JP JP2017528677A patent/JP6803840B2/ja active Active
- 2016-07-11 WO PCT/JP2016/070466 patent/WO2017010463A1/ja active Application Filing
- 2016-07-11 CN CN201680041536.5A patent/CN107849138B/zh active Active
- 2016-07-11 US US15/744,507 patent/US10730939B2/en active Active
- 2016-07-11 CN CN202110636883.5A patent/CN113336852A/zh active Pending
- 2016-07-11 KR KR1020187000902A patent/KR20180023951A/ko not_active Application Discontinuation
-
2020
- 2020-06-16 US US16/902,618 patent/US20210009683A1/en not_active Abandoned
- 2020-12-01 JP JP2020199461A patent/JP7122361B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2021046417A (ja) | 2021-03-25 |
CN107849138B (zh) | 2021-06-29 |
KR20180023951A (ko) | 2018-03-07 |
EP3323831A4 (en) | 2019-02-27 |
ES2949317T3 (es) | 2023-09-27 |
US20180237518A1 (en) | 2018-08-23 |
US20210009683A1 (en) | 2021-01-14 |
JP6803840B2 (ja) | 2020-12-23 |
EP3323831A1 (en) | 2018-05-23 |
EP3323831B1 (en) | 2023-04-12 |
JPWO2017010463A1 (ja) | 2018-07-05 |
CN107849138A (zh) | 2018-03-27 |
JP7122361B2 (ja) | 2022-08-19 |
SG10201913225SA (en) | 2020-02-27 |
CN113336852A (zh) | 2021-09-03 |
US10730939B2 (en) | 2020-08-04 |
WO2017010463A1 (ja) | 2017-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268527A (en) | Bispecific antibodies bind PD1 and LAG3 specifically | |
HK1256365A1 (zh) | 對pd1和tim3特異性的雙特異性抗體 | |
IL263542A (en) | Bispecific antibodies inhibit immunological checkpoint | |
ZA201803669B (en) | Antibodies specifically binding pd-1 and their uses | |
SG11201705252UA (en) | Anti-pd-1 monoclonal antibodies and obtaining method thereof | |
ZA201908549B (en) | Checkpoint inhibitor bispecific antibodies | |
DK3182999T3 (da) | Anti-lag3-antistoffer og antigenbindingsfragmenter | |
SG10201913225SA (en) | Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor | |
SG11201610459XA (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
SG11201709908QA (en) | Method for quantifying monoclonal antibody | |
EP3294766C0 (en) | HUMANIZED ANTIBODY OR FRAGMENT THEREOF SPECIFIC FOR CD3 | |
ZA201902120B (en) | Antibody specifically binding to pd-1 and functional fragment thereof | |
HK1256804A1 (zh) | 抗cd154抗體及其使用方法 | |
IL252008A0 (en) | Methods for producing bispecific domains, variants of antibodies and their use | |
ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
SG11202101922YA (en) | Highly versatile method for granting new binding specificity to antibody | |
SG11201705632UA (en) | Bispecific antibody binding to trailr2 and psma | |
GB201620411D0 (en) | Method and composition for determining specific antibody responses to species of filovirus | |
GB201621591D0 (en) | Antibody molecules and method | |
IL248458A0 (en) | Cry1ca-specific monoclonal antibodies and related detection methods | |
GB201516008D0 (en) | OX40L antibodies and uses thereof |